Universal Bcma Car-T
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Explore 16 assets in Chronic Inflammatory Demyelinating Polyradiculoneuropathy →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Xuanwu Hospital, Beijing
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06485232CT.gov Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Inflammatory Demyelinating Polyradiculoneuropathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Universal Bcma Car-T (this asset) | Xuanwu Hospital, Beijing | Early P1 | C · 39 |
| Human Immunoglobulins | National Center for Research Resources (NCRR) | P3 | BB |
| Amifampridine | National Center for Research Resources (NCRR) | P3 | BB |
| i10e | Laboratoire français de Fractionnement et de Biotechnologies | P3 | B |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fred Hutchinson Cancer Center | P2 | CCC |
| Etoposide | Fred Hutchinson Cancer Center | P2 | CCC |
| Cytarabine | Fred Hutchinson Cancer Center | P2 | CCC |
| Prednisone | Fred Hutchinson Cancer Center | P2 | CCC |
| Camustine | Fred Hutchinson Cancer Center | P2 | CCC |
+10 more in the Chronic Inflammatory Demyelinating Polyradiculoneuropathy cohort
Other indications for Universal Bcma Car-T
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuromyelitis Optica | — | Early P1 | C · 39 |
| Myasthenia Gravis | — | Early P1 | C · 39 |
| Multiple Sclerosis | — | Early P1 | C · 34 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Human ImmunoglobulinsNational Center for Research Resources (NCRR)BB
- AmifampridineNational Center for Research Resources (NCRR)BB
- i10eLaboratoire français de Fractionnement et de BiotechnologiesB
- Anti-Human T-Lymphocyte Immunoglobulin, RabbitFred Hutchinson Cancer CenterCCC
- EtoposideFred Hutchinson Cancer CenterCCC
Citation
Floatz Terminal. Universal Bcma Car-T in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/universal-bcma-car-t-chronic-inflammatory-demyelinating-polyradiculoneuropathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →